CELOX PPH

Today on World Suicide Prevention Day we want to encourage you to #StarttheConversation. Every conversation or chat, could make a huge difference to someone you know. Together we can change the narrative on suicide and shift the culture of silence and stigma to more openness. #WorldSuicidePreventionDay #WSPD #WSPD2024

Postpartum Haemorrhage (PPH) is a leading cause of Maternal Mortality and Morbidity affecting 14 million women around the world each year. Join us at the online CELOX PPH Expert Forum symposium on the 1st of October where leading experts on the management and treatment of PPH will share their experience, knowledge and data on the use of CELOX PPH and the impact it makes in treating PPH. Registration is via Eventbrite through the QR code or the link below:- https://lnkd.in/gkntPWgX

Calling all researchers and clinicians with an interest in maternal health. Postpartum Haemorrhage (PPH) affects millions of women every year and accounts for over 20% of all maternal deaths reported globally. The Second Global Call from the World Health Organisation is out to develop a robust evidence base for the definition of postpartum Haemorrhage (PPH). How much blood loss is too much and when do we define PPH to promote early intervention. There is substantial disagreement on several domains, including the amount of blood loss, time of measurement, inclusion of clinical signs and symptoms of haemodynamic instability, and mode of delivery. As the requirement for surgical intervention and blood transfusions increases exponentially when blood loss hits critical levels this work will be invaluable to help define new thresholds for conservative and refractory PPH management. Details in the link below #PPH #CELOXPPH #womenshealth Femi Oladapo Caitlin R. Williams

Visit the Dahlhausen booth at the 41st National Congress of the South African Society of Obstetricians & Gynaecologists to see how CELOX PPH is changing the way we manage postpartum haemorrhage and outcomes for the many young mothers who suffer needlessly from morbidity and mortality across the sub-Saharan continent. Maternal mortality rates in the region are some of the highest in the world and account for over 40% of all global deaths. CELOX PPH has a unique mode of action that stops bleeding fast ...... visit CELOX PPH or www.celoxpph.com for more information

Fantastic news on our recent exclusive agreement with KIMAL across the UK. Amazing team, looking forward to supporting your activities and bringing this life changing innovation to help prevent needless morbidity associated with postpartum haemorrhage bleeding after childbirth.

We are proud to announce an exciting new partnership with Kimal across the United Kingdom with CELOX PPH; helping clinicians manage and treat Post-Partum Haemorrhage. To learn more about how KIMAL can support you, visit www.KIMAL.com

SAVE THE DATE! Join us for the first online Expert Forum Symposium on CELOX PPH and its role in the treatment and management of Post Partum Haemorrhage. Tuesday 1st October 2024 16.00-18.10 GMT More details to follow soon

What is PPH (Post Partum Haemorrhage) and why should we care about it? PPH represents a critical condition characterised by severe bleeding that typically arises within a timeframe spanning from 24 hours to 12 weeks after childbirth and is a main cause of maternal mortality. • The global prevalence of PPH ranges from 7.2% in Oceania to as high as 25.7% in Africa. Each year, approximately 14 million women experience PPH, leading to an estimated 80,000 maternal deaths across the globe. • PPH is a serious condition that, when left untreated, can result in severe consequences, including complications related to blood transfusions, hysterectomy, disseminated intravascular coagulation (DIC), consumptive coagulopathy, multiorgan failure, organ failure, hypovolemic shock and death. • PPH is defined as an estimated blood loss exceeding 500 ml. Severe or secondary PPH is defined by a loss of 1000 ml, while massive, life-threatening PPH is attributed to a blood loss exceeding 2500 ml or the presence of hypovolemic shock. • There are a wide variety of risk factors that contribute to the occurrence of PPH, including a previous history of PPH, uterine inversion, delivery-related trauma of any cause, placenta praevia, placental abruption, uterine rupture, and multiple gestation. • A primary cause of PPH is uterine atony (insufficient contraction of the uterus following childbirth). Want to learn more about how CELOX PPH can help manage PPH visit CELOXPPH.com

Prof Wolfgang Henrich, Charité University Hospital Berlin, delivers an outstanding keynote CELOX PPH launch presentation to clinical leads across Malaysia at the OGSM in Kota Kinabalu. The interest shown during the OGSM in this transformational innovation in managing one of the leading causes of maternal mortality and morbidity across Malaysia has been unprecedented and thanks to our exclusive partners in Malaysia, Kuberan Healthcare Sdn Bhd and Yuvapandian Ramasamy for their excellent organisation of the launch event. To learn more about how we are changing the lives of young mothers around the world visit CELOX PPH or www.CELOXPPH.com

Celebrating the launch of CELOX PPH in Malaysia with our partners Kuberan Healthcare Sdn Bhd. Andy Sutcliffe will be there helping to share the news and highlighting the impact that CELOX PPH can make to the management of PPH. 100% effective in stopping Level I and II bleeds and shown to help reduce hysterectomies by 78%